Nitroprusside for Prevention of no-Reflow in Primary Angioplasty

Soroka University Medical Center

Status and phase

Terminated

Phase 4

Conditions

Myocardial Infarction

Treatments

Drug: Nitroprusside

Study type

Interventional

Funder types

Other

Identifiers

NCT00128791

sor323102ctil

Details and patient eligibility

About

In patients admitted with acute myocardial infarction, there is a total occlusion of a coronary artery. Even after emergency catheterization and angioplasty, in some patients, the resumed blood flow is suboptimal and impacts on heart function. The study is aimed at examining whether nitroprusside, an anti-hypertension medication, given directly into the coronary artery, can improve the blood flow after the removal of the obstruction that caused the infarction.

Full description

Inadequate myocardial tissue perfusion despite successful relief of the culprit occlusion and restoration of epicardial coronary flow for ST-segment elevation acute myocardial infarction (STEMI) results in poor outcome. The investigators hypothesized that nitroprusside (NTP) injected intracoronary immediately before angioplasty might prevent no-reflow and improve vessel flow and myocardial perfusion.

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Acute ST elevation myocardial infarction (MI) patients planned for primary PCI
Diagnostic angiography demonstrating a TIMI flow grade <3 in the coronary artery before the PCI

Exclusion criteria

An admission electrocardiogram (ECG) showing complete left bundle branch block or a paced rhythm
Systolic blood pressure < 90 mmHg
A history of coronary bypass operation
A known allergic reaction to nitroprusside
Chronic hemodialysis
Intravenous drug abuse
Pregnancy
Rescue intervention after failed thrombolysis
Contraindications to aspirin or clopidogrel
Need for emergent coronary artery bypass surgery
Inability to provide informed consent